Roberta Blandon, MD
Urogynecology and Reconstructive Pelvic Surgery · Park Ridge, ILNPI 1669450011
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,162 of the $2,756 with a category attached, or 78.4%. 9 manufacturers reported payments, led by Boston Scientific at 29.8% of the total. Reporting peaked in 2019 at $914 and has fallen 54.9% since, to $412 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in IL, where the typical reported total is $2,778.
Across 69 payments — averaging $39.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$821
- Coloplast$626
- Sumitomo Pharma America, Inc.$336
- Astellas Pharma US Inc$327
- Axonics, Inc.$285
- Laborie Medical Technologies Corp.$283
- plus $79 from 3 others
What the payments were for
- Travel & lodging$50918%
- Food & beverage$2,16278%
- Education$853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 12 | $821 |
| Coloplast | 6 | $626 |
| Sumitomo Pharma America, Inc. | 19 | $336 |
| Astellas Pharma US Inc | 15 | $327 |
| Axonics, Inc. | 2 | $285 |
| Laborie Medical Technologies Corp. | 12 | $283 |
| 180 Medical, Inc. | 1 | $35 |
| Convatec Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,756 in reported general payments places this provider in the 45th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 214 | $177,181 |
| GemtesaVibegron | 156 | $117,905 |
| Estradiol | 322 | $17,604 |
| Mirabegron ErMirabegron | 18 | $8,590 |
| Solifenacin Succinate | 136 | $6,524 |
| Trospium Chloride ErTrospium Chloride | 21 | $2,926 |
| Methenamine Hippurate | 32 | $2,842 |
| Trimethoprim | 42 | $2,833 |
| Trospium Chloride | 73 | $2,486 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 133 | $1,817 |
| NitrofurantoinNitrofurantoin Macrocrystal | 31 | $1,648 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $908 |
| Cephalexin | 108 | $819 |
| Clobetasol Propionate | 22 | $634 |
| Fluconazole | 28 | $225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $327 | $177,181214 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $336 | $117,905156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
Other urogynecology and reconstructive pelvic surgery in Park Ridge
- Brett VassalloPark Ridge$4K
- Michael NoonePark Ridge$3K
- Katarzyna BochenskaPark Ridge$3K
- Michael MoenPark Ridge$2K
- Kelly JirschelePark Ridge$1K
- Abraham ShashouaChicago$339K
- Peter SandSkokie$185K
- Akira GillinghamChicago$58K
- Roger GoldbergSkokie$54K
- Kimberly KentonChicago$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.